163 related articles for article (PubMed ID: 17539978)
1. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
Steinhart AH; Forbes A; Mills EC; Rodgers-Gray BS; Travis SP
Aliment Pharmacol Ther; 2007 Jun; 25(12):1389-99. PubMed ID: 17539978
[TBL] [Abstract][Full Text] [Related]
2. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
3. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis.
Ford AC; Khan KJ; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Mar; 106(3):413-20. PubMed ID: 20717106
[TBL] [Abstract][Full Text] [Related]
4. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
5. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
[TBL] [Abstract][Full Text] [Related]
7. Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease.
Rutgeerts P
Gut; 2001 Apr; 48(4):452-3. PubMed ID: 11247886
[No Abstract] [Full Text] [Related]
8. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.
Cammà C; Giunta M; Rosselli M; Cottone M
Gastroenterology; 1997 Nov; 113(5):1465-73. PubMed ID: 9352848
[TBL] [Abstract][Full Text] [Related]
9. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
Cezard JP; Munck A; Mouterde O; Morali A; Lenaerts C; Lachaux A; Turck D; Schmitz J; Maurage C; Girardet JP; Belli D; Lamireau T; Sarles J; Chouraqui JP; Descos B; Dabadi A; Meyer M; Olives JP; Mary JY
Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):31-40. PubMed ID: 19118966
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation.
Tamura S; Ishida N; Miyazu T; Onoue S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Sugimoto K
Sci Rep; 2020 Dec; 10(1):21353. PubMed ID: 33288852
[TBL] [Abstract][Full Text] [Related]
11. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
Moja L; Danese S; Fiorino G; Del Giovane C; Bonovas S
Aliment Pharmacol Ther; 2015 Jun; 41(11):1055-65. PubMed ID: 25864873
[TBL] [Abstract][Full Text] [Related]
12. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis.
Steinhart AH; Hemphill D; Greenberg GR
Am J Gastroenterol; 1994 Dec; 89(12):2116-24. PubMed ID: 7977225
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
14. Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.
Suzuki Y; Iida M; Ito H; Tachikawa N; Hibi T
Drugs R D; 2016 Mar; 16(1):35-43. PubMed ID: 26883035
[TBL] [Abstract][Full Text] [Related]
15. Interventions for prevention of post-operative recurrence of Crohn's disease.
Doherty G; Bennett G; Patil S; Cheifetz A; Moss AC
Cochrane Database Syst Rev; 2009 Oct; (4):CD006873. PubMed ID: 19821389
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Brookes MJ; Green JR
Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
[TBL] [Abstract][Full Text] [Related]
17. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
18. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
